Analysis of antibiotic resistance and clinical distribution of 6 536 isolated stains

doi:10.3877/cma.j.issn.1674-1358.2016.05.015

Abstract

Abstract:

Objective

To investigate the distribution and prevalence of antimicrobial susceptibility in the General Hospital of Shenyang Military Command during 2012-2014.

Methods

The results were analyzed according to the Clinical Laboratory Standards Institute (CLSI) breakpoints (2012, 2013 and 2014), and all data were analyzed by WHONET 5.5 and SPSS 17.0 software.

Results

Total of 6 536 isolates were collected from clinic every year from April 1st to September 30th during 2012-2014. Among which, there were 5 390 (82.47%) Gram-negative bacterial isolates and 1 146 (17.53%) Gram-positive bacterial isolates. The top three Gram-negative bacterial isolates were Acinetobacter baumannii (21.02%), Klebsiella pneumoniae (20.38%) and Pseudomonas aeruginosa (19.09%). Methicillin-resistant Staphylococcus aureus (MRSA) accounted for 41.56% from Staphylococcus aureus. All the isolates with vancomycin resistant Enterococcus faecium (VRE) accounted for 2.6%, 5.3% and 1.3% from 2012-2014, respectively. The rate of carbapenem-resistant Enterobacteriaceae (CRE) was < 1.5%, and Klebsiella pneumoniae resistant rate was lower than that of Escherichia coli. Acinetobacter baumannii had higher resistance to imipenem, with the resistant rate of 60.0% increase from 2012 to 2014, and the isolates of Pseudomonas aeruginosa were still highly susceptible to most surveillance drugs.

Conclusions

Surveillance of bacterial resistance was important and valuable for understanding the resistant pattern change in local hospital and rational selection of antimicrobial agents.

Key words: Antimicrobial agent, Bacterial resistance surveillance, Antimicrobial susceptibility testing

Desheng Lu, Minglei Zhang, Jingbo Yu, Wei Ren, Dongya Meng, Jing Liu. Analysis of antibiotic resistance and clinical distribution of 6 536 isolated stains[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(05): 583-588.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.05.015

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I05/583

Figures/Tables 6

References 20

1	Martins A, Hunyadi A, Amaral L. Mechanisms of resistance in bacteria: an evolutionary approach[J]. Open Microbiol J,2013,7(1):53-58.
2	夏晓影，贾蓓，王群, 等. 常见革兰阴性杆菌3年耐药性监测[J]. 中国抗菌药物杂志,2012,37(10):783-788.
3	胡付品，朱德妹，汪复, 等. 2013年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志,2014,14(5):365-374.
4	张小江，张辉，窦红涛, 等. 2012年北京协和医院细菌耐药性监测[J]. 中国感染与化疗杂志,2014,14(2):104-111.
5	Finan IE, Archer GL, Pucci MI, et al. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus[J]. Antimicroob Agents Chemothber,2001,45(11):3070-3075.
6	Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin-United States, 2002-2006[J]. Morb Mortal Wkly Rep,2002,51(26):565-567.
7	Sanchez Garcia M, De la Torre MA, Morales G, et a1. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit [J]. JAMA,2010,303(22):2060-2064.
8	冯慧芬，赵秋民，段广才, 等. 产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的耐药性及其危险因素分析[J]. 现代预防医学,2015,42(7):1325-1327.
9	Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of intensive care unit surv eillance cutures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia[J]. Clin Infect Dis,2006,43(8):971-978.
10	Jain R, Kralovic SM, E vans ME, et al. Veterans affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections[J]. N Engl J Med,2011,364(15):1419-1430.
11	饶绍琴，周忠华，喻华, 等. Mohnarin 2009年报告:西南地区细菌耐药监测[J]. 中国临床药理学杂志,2010,27(7):546-550.
12	牛司强，阳苹，张莉萍. 2012年重庆市细菌耐药性监测[J]. 中国抗生素杂志,2014,39(5):338-343.
13	鲍娟，戈梅，陈代杰. 治疗耐万古霉素肠球菌的药物及其耐药机制研究[J]. 世界临床药学,2011,32(11):686-691.
14	Shenoy KA, Jyothi EK, Ravikumar R. Phenotypic identification & molecular detection of bla (ndm-1) gene in multidrug resistant Gram-negative bacilli in a tertiary care centre[J]. Indian J Med Res,2014,139(4):625-631.
15	Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies[J]. Infect Contr Hospi Epidemiol,2008,29(12):1099-1106.
16	Yang QW, Wang H, Sun HL, et al. Phenotypic and genotypic characterization of Enterobact eriaceae with decreased susceptibility to carbapenems: results from large hospital based surveil lance studies in China[J]. Antimicrob Agents Chemother,2010,54(1):573-577.
17	陈向阳，闫灿. 综合性医院575株大肠埃希菌的临床分布及耐药性[J]. 现代预防医学,2015,42(14):2680-2681.
18	Davies J, Davies D. Origins and evolution of antibiotic resistance [J]. Microbiol Mol Biol Rev,2010,74(3):417-433.
19	苏扬. 2009年我院临床常见病原菌分布耐药性分析[J]. 临床和实验医学杂志,2011,10(2):117-120.
20	Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology[J]. Int J Antimicrob Agents,2015,45(6):568-585.

细菌	2012年（n = 1 654）		2013年（n = 2 192）		2014年（n = 2 690）
细菌	株数	比例（%）	株数	比例（%）	株数	比例（%）
鲍曼不动杆菌	384	23.21	490	22.35	500	18.59
肺炎克雷伯菌	294	17.78	452	20.62	586	21.78
铜绿假单胞菌	323	19.53	392	17.88	533	19.81
大肠埃希菌	233	14.09	353	16.11	426	15.84
金黄色葡萄球菌	161	9.73	140	6.39	185	6.88
嗜麦芽窄食单胞菌	108	6.53	146	6.66	170	6.32
屎肠球菌	71	4.29	118	5.38	148	5.50
表皮葡萄球菌	80	4.84	101	4.61	142	5.28

细菌	2012年（n = 1 654）		2013年（n = 2 192）		2014年（n = 2 690）
细菌	株数	比例（%）	株数	比例（%）	株数	比例（%）
鲍曼不动杆菌	384	23.21	490	22.35	500	18.59
肺炎克雷伯菌	294	17.78	452	20.62	586	21.78
铜绿假单胞菌	323	19.53	392	17.88	533	19.81
大肠埃希菌	233	14.09	353	16.11	426	15.84
金黄色葡萄球菌	161	9.73	140	6.39	185	6.88
嗜麦芽窄食单胞菌	108	6.53	146	6.66	170	6.32
屎肠球菌	71	4.29	118	5.38	148	5.50
表皮葡萄球菌	80	4.84	101	4.61	142	5.28

抗菌药物	金黄色葡萄球菌						表皮葡萄球菌
	2012年		2013年		2014年		2012年		2013年		2014年
	R	S	R	S	R	S	R	S	R	S	R	S
万古霉素	0.0	99.6	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0
庆大霉素	55.8	43.7	47.0	50.3	36.5	62.1	34.5	62.7	33.9	55.4	28.8	24.5
青霉素	93.0	7.0	88.5	11.5	89.6	10.4	96.0	4.0	97.2	2.8	90.7	9.3
红霉素	81.4	15.2	79.3	20.7	75.3	24.7	82.1	17.9	80.2	15.8	87.8	12.2
环丙沙星	64.0	34.6	49.8	41.5	37.6	59.7	57.9	38.3	68.3	26.8	52.2	38.3
利福平	12.1	87.0	9.6	83.4	4.7	93.9	6.6	93.0	11.4	85.7	2.9	94.9
复方新诺明	76.5	23.5	37.3	62.7	46.4	53.6	93.9	6.1	82.1	17.9	79.6	20.4
四环素	66.5	32.0	52.8	42.8	40.1	58.2	27.1	70.5	28.8	61.8	25.2	74.6
克林霉素	75.4	24.6	76.3	22.5	55.4	44.6	48.9	49.7	53.7	45.3	50.4	49.6
替考拉宁	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0
苯唑西林	59.6	40.4	47.7	52.3	27.8	72.2	86.0	14.0	84.4	20.6	84.0	16.0
利奈唑胺	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0

抗菌药物	金黄色葡萄球菌						表皮葡萄球菌
	2012年		2013年		2014年		2012年		2013年		2014年
	R	S	R	S	R	S	R	S	R	S	R	S
万古霉素	0.0	99.6	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0
庆大霉素	55.8	43.7	47.0	50.3	36.5	62.1	34.5	62.7	33.9	55.4	28.8	24.5
青霉素	93.0	7.0	88.5	11.5	89.6	10.4	96.0	4.0	97.2	2.8	90.7	9.3
红霉素	81.4	15.2	79.3	20.7	75.3	24.7	82.1	17.9	80.2	15.8	87.8	12.2
环丙沙星	64.0	34.6	49.8	41.5	37.6	59.7	57.9	38.3	68.3	26.8	52.2	38.3
利福平	12.1	87.0	9.6	83.4	4.7	93.9	6.6	93.0	11.4	85.7	2.9	94.9
复方新诺明	76.5	23.5	37.3	62.7	46.4	53.6	93.9	6.1	82.1	17.9	79.6	20.4
四环素	66.5	32.0	52.8	42.8	40.1	58.2	27.1	70.5	28.8	61.8	25.2	74.6
克林霉素	75.4	24.6	76.3	22.5	55.4	44.6	48.9	49.7	53.7	45.3	50.4	49.6
替考拉宁	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0
苯唑西林	59.6	40.4	47.7	52.3	27.8	72.2	86.0	14.0	84.4	20.6	84.0	16.0
利奈唑胺	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0	0.0	100.0

抗菌药物	2012年		2013年		2014年
抗菌药物	R	S	R	S	R	S
复方新诺明	82.0	18.0	27.1	72.9	69.2	30.8
苯唑西林	100.0	0.0	100.0	0.0	100.0	0.0
青霉素	100.0	0.0	100.0	0.0	100.0	0.0
利福平	26.7	72.6	22.7	69.1	23.1	76.9
克林霉素	87.5	12.5	93.0	7.0	100.0	0.0
环丙沙星	100.0	0.0	97.4	1.8	92.3	7.7
四环素	99.3	0.7	94.4	4.8	92.3	7.7
万古霉素	0.0	98.5	0.0	100.0	0.0	100.0
红霉素	90.5	2.9	98.3	1.7	100.0	0.0
利奈唑胺	0.0	100.0	0.0	100.0	0.0	100.0
替考拉宁	0.0	100.0	0.0	100.0	0.0	100.0

Please choose a citation manager

Content to export